Neuroprotective compounds for reducing neurological damage due to cellular stress in an individual are of Formula 1: ##STR00001##
or an enantiomer, diastereomer, racemic mixture or a pharmaceutically acceptable salt thereof, wherein: Ar=aryl; Y=aryl substituent (ortho, meta, or para) selected from the group consisting of: alkyl, alkyloxy, alkylamino, R.sup.5R.sup.6N, and halo; XO, N, or S; RH, alkyl, aryl, OH, alkyloxy, aryloxy, NH.sub.2, alkylamino, R.sup.5R.sup.6N, or arylamino; R.sup.1 and R.sup.2=alkylcarbonyl, arylcarbonyl, alkyl, or H, individually; R.sup.3=arylCHCH, alkylCHCH, alkyl; R.sup.4H, alkyl, or aryl; and R.sup.5 and R.sup.6=alkyl, individually. Methods of reducing neurological damage due to cellular stress in an individual include administering to the individual during or after the cellular stress a neuroprotective compound of Formula I in a therapeutically effective amount to restore synaptic function during or after the cellular stress.

Neuroprotective compounds for reducing neurological damage due to cellular stress in an individual are of Formula 1: ##STR00001##
or an enantiomer, diastereomer, racemic mixture or a pharmaceutically acceptable salt thereof, wherein: Ar=aryl; Y=aryl substituent (ortho, meta, or para) selected from the group consisting of: alkyl, alkyloxy, alkylamino, R.sup.5R.sup.6N, and halo; XO, N, or S; RH, alkyl, aryl, OH, alkyloxy, aryloxy, NH.sub.2, alkylamino, R.sup.5R.sup.6N, or arylamino; R.sup.1 and R.sup.2=alkylcarbonyl, arylcarbonyl, alkyl, or H, individually; R.sup.3=arylCHCH, alkylCHCH, alkyl; R.sup.4H, alkyl, or aryl; and R.sup.5 and R.sup.6=alkyl, individually. Methods of reducing neurological damage due to cellular stress in an individual include administering to the individual during or after the cellular stress a neuroprotective compound of Formula I in a therapeutically effective amount to restore synaptic function during or after the cellular stress.

The invention provides compounds having the general formula I:

##STR00001##

and pharmaceutically acceptable salts thereof, wherein the variables R.sup.AA, n, ring A, X.sup.1, L, m, X.sup.2, R.sup.2, R.sup.3, R.sup.4, R.sup.5, X, and R.sup.6 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

The invention provides compounds having the general formula I:

##STR00001##

and pharmaceutically acceptable salts thereof, wherein the variables R.sup.AA, n, ring A, X.sup.1, L, m, X.sup.2, R.sup.2, R.sup.3, R.sup.4, R.sup.5, X, and R.sup.6 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

A method of reducing an aromatic ring or a cyclic, allylic ether in a compound includes preparing a reaction mixture including a compound including an aromatic moiety or a cyclic, allylic ether moiety, an alkali metal, and either ethylenediamine, diethylenetriamine, triethylenetetramine, or a combination thereof, in an ether solvent; and reacting the reaction mixture at from ?20? C. to 30? C. for a time sufficient to reduce a double bond in the aromatic moiety to a single bond or to reduce the cyclic, allylic ether moiety.

A method of reducing an aromatic ring or a cyclic, allylic ether in a compound includes preparing a reaction mixture including a compound including an aromatic moiety or a cyclic, allylic ether moiety, an alkali metal, and either ethylenediamine, diethylenetriamine, triethylenetetramine, or a combination thereof, in an ether solvent; and reacting the reaction mixture at from ?20? C. to 30? C. for a time sufficient to reduce a double bond in the aromatic moiety to a single bond or to reduce the cyclic, allylic ether moiety.

The invention provides processes for the preparation of HU-910, which are scalable to industrial purposes, using safer reagents and having high yield and pure product and a crystalline structure of HU-910, which is a unique product thereof.

The invention provides processes for the preparation of HU-910, which are scalable to industrial purposes, using safer reagents and having high yield and pure product and a crystalline structure of HU-910, which is a unique product thereof.

Neuroprotective compounds for reducing neurological damage due to cellular stress in an individual are of Formula 1:

##STR00001##

or an enantiomer, diastereomer, racemic mixture or a pharmaceutically acceptable salt thereof, wherein: Ar=aryl; Y=aryl substituent (ortho, meta, or para) selected from the group consisting of: alkyl, alkyloxy, alkylamino, R.sup.5R.sup.6N, and halo; XO, N, or S; RH, alkyl, aryl, OH, alkyloxy, aryloxy, NH.sub.2, alkylamino, R.sup.5R.sup.6N, or arylamino; R.sup.1 and R.sup.2=alkylcarbonyl, arylcarbonyl, alkyl, or H, individually; R.sup.3=arylCHCH, alkylCHCH, alkyl; R.sup.4H, alkyl, or aryl; and R.sup.5 and R.sup.6=alkyl, individually. Methods of reducing neurological damage due to cellular stress in an individual include administering to the individual during or after the cellular stress a neuroprotective compound of Formula I in a therapeutically effective amount to restore synaptic function during or after the cellular stress.

The present invention provides compounds of Formula (I): ##STR00001##
or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein-coupled receptor modulators which may be used as medicaments.